Unique structural determinants for Stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744

Journal of Immunology

Volumn 176, Issue 5, 2006, Pages 2933-2941

  Shao, Huang ^a   Xu, Xuejun ^a   Jing, Naijie ^a   Tweardy, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; LIGAND; OXYGEN; PHOSPHATE; PHOSPHOPEPTIDE; PHOSPHOTYROSINE; STAT3 PROTEIN; SULFUR; TYROSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEK293; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SRC HOMOLOGY DOMAIN;

EID: 33644550632     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.5.2933     Document Type: Article

References (60)

1. Tian, S. S., P. Lamb, H. M. Seidel, R. B. Stein, and J. Rosen. 1994. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 84: 1760-1764.
2. Tweardy, D. J., T. M. Wright, S. F. Ziegler, H. Baumann, A. Chakraborty, S. M. White, K. F. Dyer, and K. A. Rubin. 1995. Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 86: 4409-4416.
3. Chakraborty, A., S. M. White, T. S. Schaefer, E. D. Ball, K. F. Dyer, and D. J. Tweardy. 1996. Granulocyte colony-stimulating factor activation of Stat3α and Stat3β in immature normal and leukemic human myeloid cells. Blood 88: 2442-2449.
4. Shimozaki, K., K. Nakajima, T. Hirano, and S. Nagata. 1997. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J. Biol. Chem. 272: 25184-25189.
5. Chakraborty, A., and D. J. Tweardy. 1998. Stat3 and G-CSF-induced myeloid differentiation. Leuk. Lymphoma 30: 433-442.
6. Ward, A. C., L. Smith, J. P. de Koning, Y. van Aesch, and I. P. Touw. 1999. Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J. Biol. Chem. 274: 14956-14962.
7. Kip1. Oncogene 19: 3290-3298.
8. McLemore, M. L., S. Grewal, F. Liu, A. Archambault, J. Poursine-Laurent. J. Haug, and D. C. Link. 2001. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14: 193-204.
9. Maun, N. A., P. Gaines, A. Khanna-Gupta, T. Zibello, L. Enriquez, L. Goldberg, and N. Berliner. 2004. G-CSF signaling can differentiate promyelocytes expressing a defective retinoic acid receptor: evidence for divergent pathways regulating neutrophil differentiation. Blood 103: 1693-1701.
10. Irish, J. M., R. Hovland, P. O. Krutzik, O. D. Perez, O. Bruserud, B. T. Gjertsen, and G. P. Nolan. 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.
11. Taniguchi, T. 1995. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268: 251-255.
12. Nicholson, S. E., A. C. Oates, A. G. Harpur, A. Ziemiecki, A. F. Wilks, and J. E. Layton. 1994. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. Proc. Natl. Acad. Sci. USA 91: 2985-2988.
13. Shimoda, K., H. Iwasaki, S. Okamura, Y. Ohno, A. Kubota, F. Arima, T. Otsuka, and Y. Niho. 1994. G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human myeloid G-CSF responsive and proliferative cells, but not in mature neutrophils. Biochem. Biophys. Res. Commun. 203: 922-928.
14. Nicholson, S. E., U. Novak, S. F. Ziegler, and J. E. Layton. 1995. District regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 86: 3698-3704.
15. de Koning, J. P., A. M. Schelen, F. Dong, C. van Buitenen, B. M. Burgering, J. L. Bos, B. Lowenberg, and I. P. Touw. 1996. Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. Blood 87: 132-140.
16. Kendrick, T. S., R. J. Lipscombe, O. Rausch, S. E. Nicholson, J. E. Layton, L. C. Goldie-Cregan, and M. A. Bogoyevitch. 2004. Contribution of the membrane-distal tyrosine in intracellular signaling by the granulocyte colony-stimulating factor receptor. J. Biol. Chem. 279: 326-340.
17. Hunter, M. G., and B. R. Avalos. 1998. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J. Immunol 160: 4979-4987.
18. Hortner, M., U. Nielsch, L. M. Mayr, J. A. Johnston, P. C. Heinrich, and S. Haan. 2002. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J. Immunol. 169: 1219-1227.
19. Chakraborty, A., K. F. Dyer, M. Cascio, T. A. Mietzner, and D. J. Tweardy. 1999. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood 93: 15-24.
20. Ward, A. C., Y. M. van Aesch, A. M. Schelen, and I. P. Touw. 1999. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 93: 447-458.
21. Songyang, Z., S. E. Shoelson, M. Chaudhuri G. Gish, T. Pawson, W. G. Haser. F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider, et al. 1993. SH2 domains recognize specific phosphopeptide sequences. Cell 72: 767-778.
22. Cantley, L. C., and Z. Songyang. 1994. Specificity in recognition of phosphopeptides by src-homology 2 domains. J. Cell Sci. Suppl. 18: 121-126.
23. Stahl, N., T. J. Farruggella, T. G. Boulton, Z. Zhong, J. E. Darnell, Jr., and G. D. Yancopoulos. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267: 1349-1353.
24. Weber-Nordt, R. M., J. K. Riley, A. C. Greenlund, K. W. Moore, J. E. Darnell, and R. D. Schreiber, 1996. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271: 27954-27961.
25. Rahuel, J., B. Gay, D. Erdmann, A. Strauss, C. Garcia-Echeverria, P. Furet, G. Caravatti, H. Fretz, J. Schoepfer, and M. G. Gratter. 1996. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat. Struct. Biol. 3: 586-589.
26. Becker, S., B. Groner, and C. W. Muller. 1998. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394: 145-151.
27. Hemmann, U., C. Gerhartz, B. Heesel, J. Sasse, G. Kurapkat, J. Grotzinger, A. Wollmer, Z. Zhong, J. E. Darnell, Jr., L. Graeve, et al. 1996. Differential activation of acute phase response factor/Stat3 and Stal1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH1 domains define the specificity of stat factor activation. J. Biol. Chem. 271: 12999-13007.
28. Caldenhoven, E., D. T. B. van Dijk, R. Solari, J. Armstrong, J. A. M. Raaijmakers, J. W. J. Lammers, L. Koenderman, and R. P. de Groot. 1996. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271: 13221-13227.
29. Shao, H., H. Y. Cheng, R. G. Cook, and D. J. Tweardy. 2003. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 63: 3923-3930.
30. Schuenke, K. W., R. G. Cook, and R. R. Rich. 1998. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum. Immunol. 59: 783-793.
31. Leatherbarrow, R. J. 1998. GraFit Version 4. Erithacus Software Ltd., Staines.
32. Ziegler, S. F.. T. Davis, J. A. Schneringer, T. L. Franklin, T. W. Tough, M. Teepe, A. Larsen, D. E. Williams, and C. A. Smith. 1991. Alternative forms of the human G-CSF receptor function in growth signal transduction. [Published erratum appears in 1992 New Biol. 4: 172.] New Biol. 3: 1242-1248.
33. van de Geijn, G. J., J. Gits, and I. P. Touw. 2004. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling. J. Leukocyte Biol. 76: 237-244.
34. Nicholson, S. E., R. Starr, U. Novak, D. J. Hilton, and J. E. Layton. 1996. Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF-induced differentiation of murine myeloid leukemic (Ml) cells. J. Biol. Chem. 271: 26947-26953.
35. Shao, H., X. Xu, M. A. Mastrangelo, N. Jing, R. G. Cook, G. B. Legge, and D. J. Tweardy. 2004. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J. Biol. Chem. 279: 18967-18973
36. Rahuel, J., C. Garcia-Echeverria, P. Furet, A. Strauss, G. Caravatti, H. Fretz, J. Schoepfer, and B. Gay. 1998. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands. J. Mol. Biol. 279: 1013-1022.
37. Birdsall, D. L., J. Finer-Moore, and R. M. Stroud. 2003. The only active mutant of thymidylate synthase D169, a residue far from the site of methyl transfer, demonstrates the exquisite nature of enzyme specificity. Protein Eng. 16: 229-240.
38. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276: 45443-45455.
39. Sadowski, I., J. C. Stone, and T. Pawson. 1986. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6: 4396-4408.
40. Sheinerman, F. B., B. Al-Lazikani, and B. Honig. 2003. Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains. J. Mol. Biol. 334: 823-841.
41. Waksman, G., S. E. Shoelson, N. Pant, D. Cowbum, and J. Kuriyan. 1993. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72: 779-790.
42. Ren, Z., L. A. Cabell, T. S. Schaefer, and J. S. McMurray. 2003. Identification of a high-affinity phosphopeptide inhibitor of stat3. Bioorg. Med. Chem. Lett. 13: 633-636.
43. Wiederkehr-Adam, M., P. Ernst, K. Muller, E. Bieck, F. O. Gombert, J. Ottl, P. Graff, F. Grossmuller, and M. H. Heim. 2003. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem. 278: 16117-16128.
44. Guruprasad, K., and S. Rajkumar. 2000. β- and γ-turns in proteins revisited: a new set of amino acid turn-type dependent positional preferences and potentials. J. Biosci. 25: 143-156.
45. Mao, X., Z. Ren, G. N. Parker, H. Sondermann, M. A. Pastorello, W. Wang, J. S. McMurray, B. Demeler, J. E. Darnell, Jr., and X. Chen. 2005. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell 17:761-771.
46. Shah, N. P., C. Tran, F. Y. Lee, P. Chen, D. Norris, and C. L. Sawyers. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
47. Noble, M. E., J. A. Endicott, and L. N. Johnson. 2004. Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1805.
48. Li, P., M. Zhang, Y. Q. Long, M. L. Peach, H. Liu, D. Yang, M. Nicklaus, and P. P. Roller. 2003. Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. Bioorg. Med. Chem. Lett. 13: 2173-2177.
49. Kawahata, N., M. G. Yang, G. P. Luke, W. C. Shakespeare, R. Sundaramoorthi, Y. Wang, D. Johnson, T. Merry, S. Violette, W. Guan, et al. 2001. A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′- phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain. Bioorg. Med. Chem. Lett. 11: 2319-2323.
50. Sawyer, T. K., R. S. Bohacek, D. C. Dalgarno, C. J. Eyermann, N. Kawahata, C. A. Metcalf, 3rd, W. C. Shakespeare, R. Sundaramoorthi, Y. Wang, and M. G. Yang. 2002. SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev. Med. Chem. 2: 475-488.
51. Gilliland, D. G., and J. D. Griffin. 2002. Role of FLT3 in leukemia. Curr. Opin. Hematol. 9: 274-281.
52. Benekli, M., Z. Xia, K. A. Donohue, L. A. Ford, L. A. Pixley, M. R. Baer, H. Baumann, and M. Wetzler. 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99: 252-257.
53. Epling-Burnette, P. K., J. H. Liu, R. Catlett-Falcone, J. Turkson, M. Oshiro. R. Kothapalli, Y. Li, J. M. Wang, H. F. Yang-Yen, J. Karras, et al. 2001. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107: 351-362.
54. Catlett-Falcone, R., T. H. Landowski, M. M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J. L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
55. Garcia, R., T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cos, R. Falcone, R. Fairclough, S. Parsons, et al. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
56. Jing, N., Y. Li, W. Xiong, W. Sha, L. Jing, and D. J. Tweardy. 2004. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 64: 6603-6609.
57. Mora, L. B., R. Buettner, J. Seigne, J. Diaz, N. Ahmad, R. Garcia, T. Bowman, R. Falcone, R. Fairclough, A. Cantor, et al. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62: 6659-6666.
58. Grandis, J. R., S. D. Drenning, A. Chakraborty, M. Y. Zhou, Q. Zeng, A. S. Pitt, and D. J. Tweardy. 1998. Requirement of Stat3 but not Stall activation for epidermal growth factor receptor-mediated cell growth In vitro. J. Clin. Invest. 102: 1385-1392.
59. Grandis, J. R., S. D. Drenning, Q. Zeng, S. C. Watkins, M. F. Melhem, S. Endo, D. E. Johnson, L. Huang, Y. He, and J. D. Kim. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 97: 4227-4232.
60. Lee, C. K., R. Raz, R. Gimeno, R. Gertner, B. Wistinghausen, K. Takeshita, R. A. DePinho, and D. E. Levy. 2002. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17; 63-72.